Vitrafy secures third U.S. blood network partnership, this time targeting platelets
Vitrafy Life Sciences Ltd (ASX: VFY) has entered into a partnership with Versiti Blood Health, Inc., a U.S. non-profit blood network, to advance development of Vitrafy’s cryopreservation ecosystem for platelets. The agreement marks Vitrafy’s third major U.S. civilian blood network partnership and its first focused specifically on platelets rather than red blood cells.
The two preceding partnerships, with Vitalant and Hoxworth Blood Center, are both centred on red blood cells. Versiti extends that civilian footprint into platelet territory, a development directly tied to the Phase II in-vitro platelet study conducted by the United States Army Institute of Surgical Research (USAISR), announced 22 May 2026, in which the 3% DMSO no-wash protocol achieved 94.4% mean post-thaw platelet recovery using Vitrafy’s cryopreservation ecosystem.
As an initial step, Vitrafy will place two cryopreservation freezing units at Versiti’s Blood Research Institute facility in Milwaukee, Wisconsin. The units will be provided without charge, and the placement will not generate revenue at this stage.
When big ASX news breaks, our subscribers know first
What this partnership actually involves
The Versiti partnership encompasses two distinct workstreams:
-
Platelet cryopreservation development: Vitrafy and Versiti will each contribute resources to advance the integration of Vitrafy’s no-wash cryopreservation ecosystem into Versiti’s platelet workflows. This work is in development and remains subject to U.S. regulatory requirements.
-
Verification and validation (V&V) activities: Blood products supplied by Versiti will support V&V activities for Vitrafy’s cryopreservation freezer, specifically for currently approved cryopreserved blood products such as plasma. These activities are directed at completing U.S. FDA medical device listing for Vitrafy’s cryopreservation freezer, targeted for FY2027. Vitrafy will fund certain V&V services undertaken by Versiti on the Company’s behalf related to this process.
Versiti has also indicated it intends to explore the application of Vitrafy’s cryopreservation ecosystem to other blood products, including red blood cells.
| Workstream | Focus | Stage | Revenue? |
|---|---|---|---|
| Platelet cryopreservation | No-wash platelet workflows | Development | No |
| V&V activities | FDA medical device listing (freezer) | Regulatory pathway | No |
Why platelet shelf life is the problem Vitrafy is solving
Platelets are a component of blood used to help patients stop bleeding, commonly required in surgeries, cancer treatments, and trauma care. Under current standard storage conditions, platelets have a shelf life of just 7 days, which creates persistent supply challenges for hospitals that need to match demand with a product that expires quickly.
The consequences are significant. According to a Washington Post report cited in the announcement, 33% of hospitals report facing platelet shortages in life-saving scenarios. Hospitals cannot reliably stockpile platelets the way they can other medical supplies, leaving them vulnerable to unexpected surges in demand.
Cryopreservation, which involves freezing biological materials to extend their usable life, is a potential solution to this constraint. If platelets can be safely frozen and thawed without significant degradation, supply chain flexibility improves considerably. Vitrafy’s no-wash protocol, which achieved 94.4% mean post-thaw platelet recovery in the USAISR Phase II study, is designed to make that possible. The use of Vitrafy’s ecosystem for cryopreserved platelets remains in development and is subject to U.S. regulatory requirements before any commercial application could proceed.
The Phase II US Army platelet study, conducted independently by USAISR across 20 donors at commercial volumes, found that all protocols tested exceeded FDA, AABB, and European regulatory guidelines for platelet quality, with no FDA-approved no-wash cryopreserved platelet product currently on the market to compete against it.
U.S. regulatory listing on track for FY2027
Versiti’s role in this partnership extends beyond research collaboration. By supplying blood products for V&V activities, Versiti is a direct contributor to Vitrafy’s pathway toward U.S. FDA medical device listing for its cryopreservation freezer, with that listing targeted for FY2027. This dual function, as both a development partner and a regulatory enabler, is what distinguishes Versiti from a standard research arrangement.
Versiti’s scale reinforces the credibility of that contribution. The organisation operates 42 fixed collection centres and serves more than 400+ hospitals across five Midwest states: Illinois, Indiana, Michigan, Ohio, and Wisconsin. Its Blood Research Institute conducts research in hematology, transfusion medicine, and cellular therapy, and operates diagnostic laboratories.
Brent Owens, Managing Director and CEO
“The Versiti partnership is the third major civilian blood network to come to us directly off the back of the USAISR platelets studies, and the first focused specifically on platelets. Vitrafy’s aim is to help supply hospitals with high-quality cryopreserved platelets — overcoming the seven-day shelf life that constrains today’s supply and easing the platelet shortages that 33% of hospitals report facing in life-saving scenarios every day.”
For investors, the V&V workstream links this partnership directly to a defined near-term regulatory milestone rather than open-ended research activity. The FY2027 U.S. medical device listing target remains the central near-term marker on Vitrafy’s regulatory roadmap, and Versiti now plays a concrete role in supporting progress toward it.
For investors exploring the broader context behind these milestones, our full explainer on Vitrafy’s FY2026 results and FY2027 regulatory roadmap covers the company’s $41.2m cash position, the full list of five commercial partnerships signed across blood and animal reproduction, and management’s framing of the 2027 legacy technology phase-out as a forcing event for adoption.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.